Sir, My attention has been drawn to correspondence about this subject. There is reference to an article in which I reported study of a series of children with osteogenesis imperfecta with special reference to the occurrence of metaphyseal fractures. 1
Sir, My attention has been drawn to correspondence about this subject. There is reference to an article in which I reported study of a series of children with osteogenesis imperfecta with special reference to the occurrence of metaphyseal fractures. At the time of our report further studies of this use of growth hormone were precluded by the withdrawal of pituitary growth hormone after reports of CreutzfeldtJakob disease. Now that a growth hormone produced by recombinant DNA technology is available, however, the choice of growth hormone over a somatostatin analogue has advantages.
Somatostatin has a very broad range of endocrine activity,' with unwanted effects upon other endocrine axes that do not appear to be produced by growth hormone. Furthermore, on simply practical grounds growth hormone, unlike somatostatin, is available in most regional centres.
In the infant with hyperinsulism, when it is necessary to temporise before surgery, we believe that growth hormone may be preferable, and its use certainly merits further study.
